Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization

Cancer Research

Volumn 61, Issue 22, 2001, Pages 8105-8109

  Kotera, Y ^a   Shimizu, K ^a   Mule J J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; INTERLEUKIN 12; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CELL DEATH; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; FEMALE; IMMUNOTHERAPY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; ULTRAVIOLET B RADIATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; APOPTOSIS; BONE MARROW CELLS; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HSP70 HEAT-SHOCK PROTEINS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NECROSIS;

EID: 0035890823     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
2. The induction of tolerance by dendritic cells that have captured apoptotic cells
3. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
4. Natural adjuvants: Endogenous activators of dendritic cells
5. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
6. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kB pathway
7. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor specific immunity
8. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection
9. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
10. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
11. Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
12. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells
13. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses
14. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: An in vitro model for assessment of tumor vaccines
15. Dendritic cells with apoptotic tumors have antitumor effects when combined with IL-2
16. Local administration of dendritic cells inhibits established breast tumor growth: Implications for apoptosis-inducing agents
17. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2
18. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
19. Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells
20. Heat shock protein 70 induced during tumor cell killing induces Thl cytokines and targets immature dendritic cell precursors to enhance antigen uptake